Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

@article{Oh2011MulticenterPI,
  title={Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.},
  author={William K Oh and Matthew David Galsky and Walter M. Stadler and S Balaji Srinivas and Franklin M. Chu and Glenn J. Bubley and Jill Goddard and Joi L Dunbar and Robert W. Ross},
  journal={Urology},
  year={2011},
  volume={78 3},
  pages={626-30}
}
OBJECTIVE To evaluate clinical activity and safety of retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC). METHODS A single-arm trial was conducted in 2 cohorts: group 1, chemotherapy naive; group 2, docetaxel-treated. IPI-504 was administered intravenously at 400 mg/m2 on days 1, 4, 8, and 11 of a 21-day… CONTINUE READING